Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus

Journal of Acquired Immune Deficiency Syndromes

Volumn 43, Issue 1, 2006, Pages 6-14

  Van Rompay, Koen K A ^a   Kearney, Brian P ^b   Sexton, Jonathan J ^a   Colón, Roxana ^a   Lawson, Jonathan R ^a   Blackwood, Emily J ^a   Lee, William A ^b   Bischofberger, Norbert ^b   Marthas, Marta L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GS 7340; TENOFOVIR DISOPROXIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST FEEDING; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG EFFICACY; INFECTION PREVENTION; INFECTION RATE; LOW DRUG DOSE; MACACA; MONKEY DISEASE; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; SINGLE DRUG DOSE; THERAPY EFFECT; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIREMIA; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ADENINE; ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTI-HIV AGENTS; GENETIC PREDISPOSITION TO DISEASE; MACACA MULATTA; PHOSPHONIC ACIDS; PRODRUGS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRULENCE;

EID: 33748097643     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000224972.60339.7c     Document Type: Article

References (48)

1. Scarlatti G. Mother-to-child transmission of HIV-1: advances and controversies of the twentieth centuries. AIDS Rev. 2004;6:67-78.
2. Gaillard P, Fowler M-G, Dabis F, et al. Use of antiretroviral drugs to prevent HIV-1 transmission through breastfeeding: from animal studies to randomized clinical trials. J Acquir Immune Defic Syndr. 2004;35:178-187.
3. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173-1180.
4. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet. 1999;354:795-802.
5. The Breastfeeding and HIV International Transmission Study (BHITS) Group. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis. 2004;189:2154-2166.
6. John-Stewart G, Mbori-Ngacha D, Ekpini R, et al. Breastfeeding and transmission of HIV-1. J Acquir Immune Defic Syndr. 2004;35:196-202.
7. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362:859-868.
8. Shapiro RL, Ndung'u T, Lockman S, et al. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. J Infect Dis. 2005;192:713-719.
9. Rousseau CM, Nduati RW, Richardson BA, et al. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast-milk and of its relationship to infant infection and maternal disease. J Infect Dis. 2003;187:741-747.
10. Kilewo C, Karlsson K, Massawe A, et al. Prevention of mother to child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania. Paper presented at: Third International AIDS Society Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro. TuPe5.3P01.
11. Shetty AK, Coovadia HM, Mirochnick MM, et al. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr. 2003;34:482-490.
12. Eshleman SH, Guay LA, Mwatha A, et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses. 2004;20:595-599.
13. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently. A cohort and case-control study. J Acquir Immune Defic Syndr. 2004;37:1489-1495.
14. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20:743-746.
15. Tsai C-C, Follis KE, Beck TW, et al. Prevention of simian immunodeficiency virus infection in macaques by 9-(2-phosphonylmethoxypropyl) adenine (PMPA). Science. 1995;270:1197-1199.
16. Van Rompay KKA, Marthas ML, Lifson JD, et al. Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retroviruses. 1998;14:761-773.
17. Mori K, Yasumoti Y, Sawada S, et al. Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection. J Virol. 2000;74:5747-5753.
18. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol. 2000;74:9771-9775.
19. Tsai C-C, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl)adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol. 1998;72:4265-4273.
20. Lifson JD, Rossio JL, Arnaout R, et al. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J Virol. 2000;74:2584-2593.
21. Van Rompay KKA, Berardi CJ, Aguirre NL, et al. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS. 1998;12:F79-F83.
22. Van Rompay KKA, McChesney MB, Aguirre NL, et al. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis. 2001;184:429-438.
23. Deeks SG, Barditch-Crovo P, Lietman PS, et al. Safety, pharmacokinetics and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl] adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother. 1998;42:2380-2384.
24. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1 infected adults. Antimicrob Agents Chemother. 2001;45:2733-2739.
25. Van Rompay KKA, Schmidt KA, Lawson JR, et al. Topical administration of low-dose tenofovir disoproxyl fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus. J Infect Dis. 2002;186:1508-1513.
26. Lee WA, He GX, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005;49:1898-1906.
27. Van Rompay KKA, Abel K, Lawson JR, et al. Attenuated poxvirus-based SIV vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr. 2005;38:124-134.
28. National Research Council. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press; 1996.
29. Van Rompay KKA, Marthas ML, Ramos RA, et al. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3′-azido-3′- deoxythymidine prevents SIV infection. Antimicrob Agents Chemother. 1992;36:2381-2386.
30. Van Rompay KKA, Singh RP, Pahar B, et al. CD8+ cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J Virol. 2004;78:5324-5337.
31. Abel K, Rocke DM, Chohan B, et al. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol. 2005;79:12164-12172.
32. Miller CJ, Li Q, Abel K, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol. 2005;79:9217-9227.
33. Van Rompay KKA, Singh R, Brignolo L, et al. The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunological parameters. J Acquir Immune Defic Syndr. 2004;36:900-914.
34. Van Rompay KKA, Brignolo LL, Meyer DJ, et al. Biological effects of short-term and prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA; tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother. 2004;48:1469-1487.
35. Van Rompay KKA, Otsyula MG, Marthas ML, et al. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother. 1995;39:125-131.
36. Van Rompay KKA, Cherrington JM, Marthas ML, et al. 9-[2- (Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother. 1996;40:2586-2591.
37. Van Rompay KKA, Matthews TB, Higgins J, et al. Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol. 2002;76:6083-6092.
38. Rodman J, Flynn P, Shapiro D, et al. Pharmacokinetics (PK) and safety of tenofovir disoproxil fumarate (TDF) in HIV-1 infected pregnant women and their infants. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. S-115.
39. Gallant J, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis. 2003;37:944-950.
40. Hazra R, Balis FM, Tullio AN, et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 2004;48:124-129.
41. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43:595-612.
42. Van Rompay KKA, Dailey PJ, Tarara RP, et al. Early short-term 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) treatment favorably alters subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques. J Virol. 1999;73:2947-2955.
43. Subbarao S, Otten R, Ramos A, et al. Chemoprophylaxis with oral tenofovir disoproxil fumarate (TDF) delays but does not prevent infection in rhesus macaques given repeated rectal challenges of SHIV. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA. Abstract 136LB.
44. Balzarini J, Van Herrewege Y, Vanham G. Metabolic activation of nucleoside and nucleotide reverse transcriptase inhibitors in dendritic and Langerhans cells. AIDS. 2002;16:2159-2163.
45. Van Herrewege Y, Penne L, Vereecken C, et al. Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission. AIDS Res Hum Retroviruses. 2002;18:1091-1102.
46. Robbins BL, Srinivas RV, Kim C, et al. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother. 1998;42:612-617.
47. Aquaro S, Caliò R, Balzarini J, et al. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res. 2002;55:209-225.
48. AIDS Vaccine Advocacy Coalition. Will a pill a day prevent HIV? Anticipating the results of the tenofovir "PREP" trials. March 2005. Available at: http://avac.org/pdf/tenofovir.pdf.